ID   A549-hACE2 [Invivogen]
AC   CVCL_A5KA
DR   cancercelllines; CVCL_A5KA
DR   InvivoGen; a549-hace2
DR   Wikidata; Q107113335
CC   Group: SARS-CoV-2 research cell line.
CC   Population: Caucasian.
CC   Characteristics: Permissive to infection by SARS-CoV-2 and/or spike-pseudotyped lentiviral particles (InvivoGen=a549-hace2).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:13557; ACE2.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 10-04-25; Version: 8
//